U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07248865) titled 'A Phase 1 Study of CLYM116 in Normal Healthy Volunteers' on Nov. 18.
Brief Summary: This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: CLYM116
CLYM116 to be administered by SC injection
DRUG: Placebo
Placebo solution to be administered at a matching volume by SC injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Climb Bio, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....